Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4931 - ISO-CC-005; a phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin _ bevacizumab in patients with metastasizing colorectal cancer

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Clinical Research

Tumour Site

Colon and Rectal Cancer

Presenters

Göran Carlsson

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

G.U. Carlsson1, T.K. Guren2, J. Haux3, P. Pfeiffer4, H. Taflin5, D. Mavroudis6, V. Georgoulias7, C. Papadimitriou8, N. Kentepozidis9, D. Boumpas10, L. Skintemo11, K.M.E. Ganlöv12, B. Gustavsson13

Author affiliations

  • 1 Department Of Surgery, Sahlgrenska University Hospital, 41685 - Gothenburg/SE
  • 2 The Norwegian Radium Hospital, Oslo University Hospital, 424 - Oslo/NO
  • 3 Department Of Surgery, Skaraborg Hospital, 54185 - Skövde/SE
  • 4 Experimental Research In Medical Cancer Therapy, Odense University Hospital, 5000 - Odense C/DK
  • 5 Department Of Surgery, Sahlgrenska University Hospital, 41345 - Gothenburg/SE
  • 6 Medical Oncology, University General Hospital, 71110 - Heraklion/GR
  • 7 Oncology, IASO General Hospital, 15562 - Cholargos Athens/GR
  • 8 Oncology, Alexandra Hospital, 115 28 - Athens/GR
  • 9 Oncology, 251 Hellenic Airforce General Hospital, 115 25 - Athens/GR
  • 10 Oncology, University Hospital Attikon, 12462 - Chaidari Athens/GR
  • 11 Clinical Reserach, Isofol Medical AB, 41346 - Gothenburg/SE
  • 12 Medical, Isofol Medical AB, 413 46 - Gothenburg/SE
  • 13 Surgical oncology Lab, University of Gothenburg, 40530 - Goteborg/SE
More

Resources

Abstract 4931

Background

Chemotherapy treatment of Colorectal Cancer, often include 5-Fluorouracil (5- FU). 5-FU inhibits the enzyme thymidylate synthase (TS), stopping the supply of thymidine for DNA synthesis. 5-FU is always combined with a folate, which enhances the 5-FU effect. Marketed folates such as LV/L-LV are prodrugs needing enzymatic conversion. Arfolitixorin (formerly Modufolin®) is the natural, biologically active form of the folates and is expected to be efficacious in a larger proportion of patients with less inter- and intra-individual variability.

Methods

ISO-CC-005 is a multi-center, phase I/II study in mCRC patients eligible for 5-FU/folate therapy alone or in combination with irinotecan or oxaliplatin ± bevacizumab. The study investigates safety and tolerability of arfolitixorin at 4 dose levels by analysing the number and severity of AEs, SAEs and DLTs. Efficacy is evaluated as ORR after 4 cycles of chemotherapy. Gene expression, deoxyuridine levels as an indirect marker of TS inhibition and time to death is also investigated. 3-6 patients per cohort are included. All receives arfolitixorin twice every two weeks during at least 4 cycles of chemotherapy.

Results

Today, 67 patients have been enrolled and 59 have initiated treatment. 13 are 1st line patients, 16 are in 2nd line, 10 are in 3rd line and 1 is in 5th treatment line. 27 SAEs have been reported in 13 patients, 6 of these were judged as at least possibly related to arfolitixorin. No SAE were judged as solely related to arfolitixorin. 49 patients have today been evaluated for efficacy. ORR 1st line patients (n = 14) at 8 weeks All 43% (6 PR, 7 SD, 1PD) Patients with arfolitixorin dose ≥60 mg/m2 56% (5 PR, 3 SD, 1 PD) Patients with arfolitixorin dose ≥60 mg/m2 + oxaliplatin 60% (3 PR, 1 SD, 1 PD).

Conclusions

The lack of need for metabolic activation makes arfolitixorin a better candidate than LV/L-LV for improved outcome of 5-FU-based chemotherapy regimens in mCRC. The ISO-CC-005 study evaluates arfolitixorin in combination with 5-FU, irinotecan, oxaliplatin ± bevacizumab in mCRC patients in 4 countries in Europe. The results, so far, for both safety and efficacy seems promising.

Clinical trial identification

EudraCT: 2014-001862-84; NCT02244632.

Legal entity responsible for the study

Isofol Medical AB.

Funding

Isofol Medical AB.

Editorial Acknowledgement

Disclosure

P. Pfeiffer: Advisory board member: Isofol Medical AB. H. Taflin: Family member is the founder of, have a leadership role, owns shares, have an advisory role, have conducted funded research, hold patents and have received travel expenses: Isofol Medical AB. L. Skintemo, K.M.E. Ganlöv: Employee, stock ownership: Isofol Medical AB. B. Gustavsson: Founder of, have a leadership role, owns shares, advisory role, conducted funded research, hold patents, received travel expenses: Isofol Medical AB. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.